



Published in final edited form as:

Nature. 2020 June ; 582(7810): 109–114. doi:10.1038/s41586-020-2227-7.

## Mouse models of neutropenia reveal progenitor-stage-specific defects

David E. Muench<sup>1,2</sup>, Andre Olsson<sup>1</sup>, Kyle Ferchen<sup>1,3</sup>, Giang Pham<sup>4</sup>, Rachel A. Serafin<sup>1</sup>, Somchai Chutipongtanate<sup>3,5</sup>, Pankaj Dwivedi<sup>3</sup>, Baobao Song<sup>1,6</sup>, Stuart Hay<sup>7</sup>, Kashish Chetal<sup>7</sup>, Lisa R. Trump-Durbin<sup>8</sup>, Jayati Mookerjee-Basu<sup>9</sup>, Kejian Zhang<sup>10</sup>, Jennifer C. Yu<sup>11,12</sup>, Carolyn Lutzko<sup>8</sup>, Kasiani C. Myers<sup>13</sup>, Kristopher L. Nazor<sup>14</sup>, Kenneth D. Greis<sup>3</sup>, Dietmar J. Kappes<sup>8</sup>, Sing Sing Way<sup>4</sup>, Nathan Salomonis<sup>7,\*</sup>, H. Leighton Grimes<sup>1,8,\*</sup>

<sup>1</sup>Division of Immunobiology and Center for Systems Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. <sup>2</sup>Molecular and Developmental Biology Graduate Program, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. <sup>3</sup>Department of Cancer Biology, University of Cincinnati, Cincinnati, Ohio, USA <sup>4</sup>Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA <sup>5</sup>Pediatric Translational Research Unit, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand <sup>6</sup>Immunology Graduate Program, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. <sup>7</sup>Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. <sup>8</sup>Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA <sup>9</sup>Fox Chase Cancer Center, Philadelphia, PA, USA. <sup>10</sup>Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. <sup>11</sup>Division of Pediatric Hematology/Oncology, Rady Children's Hospital San Diego, San Diego, California <sup>12</sup>Department of Pediatrics, University of California, San Diego, La Jolla, California <sup>13</sup>Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. <sup>14</sup>BioLegend, Inc., San Diego, CA, USA.

### Summary Paragraph

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\***Correspondence:** Nathan Salomonis, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., MLC 7038, Cincinnati, OH 45229, 650-576-1646, [Nathan.Salomonis@cchmc.org](mailto:Nathan.Salomonis@cchmc.org), H. Leighton Grimes, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., MLC 7038, Cincinnati, OH 45229, 513-636-6089, [Lee.Grimes@cchmc.org](mailto:Lee.Grimes@cchmc.org) (H.L.G.).

#### Author Contributions

DEM, GP, SSW and HLG designed experiments. DEM, AO, GP, RS, SC, and PD performed experiments and also analyzed data with KG, KZ, JY, and KCM provided patient samples and data. LRT and CL generated and cultured iPSC. JM and DJK generated the *Gfi1*<sup>N382S</sup>, *Gfi1*<sup>K403R</sup>, and *Gfi1*<sup>R412X</sup> mice. NS conceived and developed the cellHarmony software with significant input from HLG. SH and NS developed the gene viewer. KF, BS, KC, KLN, NS and HLG analyzed bioinformatics data. DEM, NS and HLG wrote the paper.

The authors declare the following competing interests: DEM is currently employed by Eli Lilly and Company and KLN is employed by BioLegend Inc. The remaining authors declare no competing interests.

**Supplementary Information** is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature)

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Supplementary Methods.** Please see the Supplementary Information for additional methods descriptions.

Advances in genetics and sequencing reveal a plethora of disease-associated and disease-causing genetic alterations. Resolving causality between genetics and disease requires generating accurate models for molecular dissection; however, the rapid expansion of single-cell landscapes presents a major challenge to accurate comparisons between mutants and their wild-type equivalents. Here, we generated mouse models of human severe congenital neutropenia (SCN) using patient-derived mutations in the Growth factor independent-1 (GFI1) transcription factor. To delineate the impact of SCN mutations, we generated single-cell references for granulopoietic genomic states with linked epitopes<sup>1</sup>, aligned mutant cells to their wild-type equivalent and identified differentially expressed genes and epigenetic loci. We find that Gfi1-target genes are altered sequentially, as cells traverse successive states during differentiation. These cell-state-specific insights facilitated genetic rescue of granulocytic specification but not post-commitment defects in innate-immune effector function; underscoring the importance of evaluating the impact of mutations and therapy within each relevant cell state.

---

## Introduction

In severe congenital neutropenia (SCN) patients, inherited and *de novo* mutations lead to a profound block in neutrophil granulopoiesis. We introduced SCN-patient mutations in the Growth factor independent-1 (GFI1) transcription factor into the murine *Gfi1* allele, which resulted in steady-state murine dysgranulopoiesis and broad *in vivo* susceptibility to neutrophil-dependent pathogens. Notably, SCN mutations divorce neutropenia from *Gfi1*<sup>-/-</sup> defects in hematopoietic stem cell and lymphocyte numbers. To delineate mechanism, we mapped the successive genomic states encompassing neutrophil granulocyte specification (capacity to form neutrophils) and commitment (cell-fate restriction)<sup>2</sup>, including a new transitional intermediate (see online viewer<sup>3</sup>), then confirmed the trajectory. Using comparative genomics<sup>4,5</sup> we assigned Gfi1-mutant cells to wild-type cell states to determine differential single-cell gene expression and chromatin. Few Gfi1-target genes are deregulated across granulopoiesis, but are instead deregulated in successive granulopoietic cell states; associated with failure of Gfi1-bound chromatin to close after specification. However, genetically rescuing specification did not resolve post-commitment defects in immune defense in mice or in G-CSF-rescued human SCN patient neutrophils. These experiments underscore the dominance of cell state in integrating the impact of both mutations and therapy, and illustrate a workflow that can be broadly applied to molecularly dissect translationally-relevant models of disease.

## Patient mutations induce neutropenia

Clinical resequencing of 225 neutropenia-patients identified previously-reported<sup>6,7</sup> and novel *GFI1* sequence polymorphisms of unknown significance (Supplementary Information), which we screened for defects in repressing an *Irf8-eGFP*-reporter allele<sup>8</sup> (Extended Data Fig. 1a, b). Next, we edited endogenous murine *Gfi1* alleles to introduce N382S, K403R, or R412X mutations (Fig. 1a, Extended Data Fig. 1c–h, phenotypic summary: Supplementary Information). Mutant Gfi1 proteins accumulate normally, but R412X mutation results in a smaller, less abundant protein (Fig. 1b, Extended Data Fig. 1i). On postnatal day 1, only *Gfi1*<sup>N382S/+</sup> mice exhibit a blunted response to neonatal gut-

bacteria-driven cues<sup>9</sup>, comparable to the exacerbated clinical presentation of SCN in neonatal humans (Extended Data Fig. 1j, k). Human *GFII* is predicted to be imprinted.<sup>10</sup> RNAScope analysis with *GFII* intronic probes (Extended Data Fig. 1l) revealed a pattern consistent with monoallelic expression.<sup>11</sup> Human induced pluripotent stem cells (iPSC) with one *GFII*<sup>R412X</sup> allele only express the mutant *GFII* allele (Extended Data Fig. 1m), and are blocked in granulopoiesis (Extended Data Fig. 1n, o). Therefore, to mimic predicted human gene regulation we genetically silenced one *Gfi1* allele<sup>12</sup> to find *Gfi1*<sup>R412X/-</sup>, *Gfi1*<sup>N382S/-</sup>, and *Gfi1*<sup>-/-</sup> neonatal mice profoundly neutropenic (Extended Data Fig. 1j, k). Peripheral blood revealed a range of neutropenia (Fig. 1c, Extended Data Fig. 2a), and *Gfi1*<sup>R412X/-</sup> and *Gfi1*<sup>N382S/-</sup> mice exhibited monocytosis as a result of cell-intrinsic lineage skewing (Fig. 1c, d, Extended Data Fig. 2a–c), supported by a lack of mature neutrophils in the bone marrow (Extended Data Fig. 2d–f). *Gfi1*<sup>R412X/-</sup> neutrophils exhibited abnormal or immature morphologies (Fig. 1c), suggesting a Gfi1 function beyond neutrophil specification. Notably, *Gfi1*<sup>-/-</sup>, *Gfi1*<sup>N382S/-</sup>, *Gfi1*<sup>R412X/-</sup> mice display steady-state Sca-1<sup>+</sup> emergency granulocyte-monocyte-progenitor gate cells (eGMP)<sup>13,14</sup> (Extended Data Fig. 3a). However, like SCN-patient serum<sup>15</sup>, extensive profiling of *Gfi1*<sup>R412X/-</sup> serum revealed elevated G-CSF, but not eGMP-associated inflammatory cytokines (Extended Data Fig. 3b–c, Supplementary Information).

Unlike *Gfi1*<sup>-/-</sup> mice, numbers of phenotypic hematopoietic stem cells (HSC) were normal in mutants (Fig. 1e, but *Gfi1*<sup>N382S/-</sup> HSC fitness was defective after transplantation. In contrast, *Gfi1*<sup>R412X/-</sup> HSC rescue lethal irradiation, but display a modest defect in chimerism during competitive transplant (Extended Data Fig. 3d, e). Similar to *Gfi1*<sup>-/-</sup> mice<sup>12,16–18</sup>, *Gfi1*<sup>N382S/-</sup> mutants displayed several defects, including runting, lymphopenia, splenomegaly (Fig. 1f, Extended Data Fig. 2b), and rarely survive to adulthood. However, neither *Gfi1*<sup>K403R/-</sup> nor *Gfi1*<sup>R412X/-</sup> mutants recapitulate these *Gfi1*<sup>-/-</sup> defects (Extended Data Fig. 2b, 3d, e), so we focused on *Gfi1*<sup>K403R/-</sup> and *Gfi1*<sup>R412X/-</sup> mice to isolate Gfi1 control of granulopoiesis.

*Gfi1*<sup>R412X/-</sup> mice were susceptible to *Candida albicans* with reduced survival and increased pathogen burden (Fig. 1g, Extended Data Fig. 3f). By contrast, *Gfi1*<sup>R412X/-</sup> and *Gfi1*<sup>K403R/-</sup> mice showed increased susceptibility to *Staphylococcus aureus* (Fig. 1h, Extended Data Fig. 3g). Impaired host defense in *Gfi1*<sup>R412X/-</sup> mice likely does not reflect reduced Gfi1 protein levels, since *Gfi1*<sup>R412X/R412X</sup> partially restored Gfi1 protein levels (Extended Data Fig. 3h), and neutrophil numbers (Fig. 1i) albeit with abnormal morphology (Fig. 1j) but failed to rescue susceptibility to *C. albicans* and *S. aureus* (Fig. 1k, l). Thus, Gfi1 control of granulocyte production is functionally dissociated from innate host defense against invasive microbial infection.

## Neutrophil specification and commitment

First, we established the genomic states encountered during neutrophil granulopoiesis using a novel flow gate (“GMP-P”) (Extended Data Fig. 4a), with reciprocal expression of Ly6g (a granulocytic marker) and CD115 (*Csf1r*, a monocytic marker) based on CD11b (Fig. 2a, b, Extended Data Fig. 4a). Histological forms, a transgenic cell cycle reporter (Fucci2)<sup>19</sup>, and transgenic reporters for *Gfi1*, *Irf8* and *Myc* validated cells undergoing terminal

granulopoiesis (Fig. 2c–e and Extended Data Fig. 4a). Notably, *Gfi1* expression is highest in CD11b<sup>int</sup>Ly6g<sup>neg</sup> cells (Fig. 2e). These analyses suggest that CD11b<sup>int</sup>Ly6g<sup>neg</sup> cells are specifying, while CD11b<sup>high</sup>Ly6g<sup>neg-high</sup> cells are committing to neutrophil granulopoiesis. We captured these cells (Extended Data Fig. 4b, c) and incorporated them into prior scRNA-Seq data<sup>20,21</sup> (Extended Data Fig. 4d and Supplementary Information). An unsupervised discovery workflow (ICGS)<sup>20</sup> (Extended Data Fig. 4c) revealed a dramatic shift in gene expression between early (specifying proNeu) and late (committed preNeu) granulocytic clusters, as well as a transitional population (preNeu-1) expressing both programs (proNeu, preNeu, immNeu names adapted from a review<sup>22</sup>). To validate the cluster order we identified known reciprocal patterns of transcription factor genes (*Irf8/Gfi1*, *Myc/Mxd1* and *Cebpa/Cebpe*), as well as primary (*Elane*, *Mpo*), secondary (*Camp*, *Lcn2*, *Ltf*), and tertiary (*Mmp8*, *Mmp9*) granule-protein genes (Fig. 2f) whose expression was significantly correlated to individual clusters (Fig. 2g). We delineated surface markers that are statistically correlated to ICGS clusters (Fig. 2h, i and Extended Data Fig. 4e–g) to find those that are extinguished (*Cd34*, *Csf1r*, *Kit*) or induced (*Itgam*, *Ly6g*, *Cd177*). Surprisingly, *Vcam1* is uniquely expressed in granulocyte-specifying cells, as confirmed by Vcam1/CD106-flow-cytometric analysis and 3D visualization of GMP-P gate cells (Fig. 2e) similar to the *Gfi1* reporter (Fig. 2e). Cell-cycle gene expression terminated in the last cluster (Extended Data Fig. 4h–l), along with an overall decrease in expressed genes at the preNeu-1 stage independent of the number of reads per cell (Extended Data Fig. 4m, suggesting that global transcriptional silencing is concomitant with granulocytic commitment.

To directly link GMP-P flow gates (Fig. 2a, Extended Data Fig. 4a) to cell clusters (Extended Data Fig. 4c), we performed cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq)<sup>1</sup> (Fig. 2j, Extended Data Fig. 5a). We supervised analysis of the CITE-Seq data using centroids of ICGS clusters (Extended Data Fig. 4c and <sup>20</sup>) to classify the newly captured cells (Extended Data Fig. 5b–e), which replicated mixed-lineage and specifying cell states (including Multi-Lin\*<sup>20</sup>, IG2<sup>20</sup> and preNeu-1 transitional populations) (Extended Data Fig. 5b, d) with no apparent sex-based bias in any cluster (Extended Data Fig. 5b, bottom). Myeloid-associated, cell cycle, and surface-marker gene expression in the CITE-Seq data displayed similar trends (compare Fig. 2f, g and Extended Data Fig. 4h–k to Extended Data Fig. 5f–i). Transformed antibody-dependent-tag (ADT) counts revealed patterns closely resembling FACS data (compare Extended Data Fig. 5a with Extended Data Fig. 5e). Surprisingly, Ly6g surface expression is discordant with the underlying processes; creating overlap between preNeu and immNeu clusters. Plotting ICGS-clusters or individual genes (significantly correlated to clusters) illustrates a similar progression through the CD11b versus Ly6g plots (Fig. 2j, k, Extended Data Fig. 5j, k). Plotting the top 1% of cells expressing *Gfi1*, *Irf8*, *Csf1r*, *Myc/Mxd1*, *Cebpa/Cebpe*, and *Vcam1* (Fig. 2k) confirmed the trajectory, which was further evidenced using pseudotemporal ordering with URD<sup>23</sup> (Fig. 2l, top). Clusters were confirmed in a published data set<sup>24</sup> (Extended Data Fig. 5l), and reconciled to reported neutrophil progenitor subsets (NMP,<sup>25</sup> NeuP,<sup>26</sup> preNeu,<sup>27</sup> and NeP<sup>24</sup>) using 13 of the surface markers used to identify them. Notably, NMP, NeuP, preNeu, and NeP span multiple ICGS clusters (Extended Data Fig. 5m, n). Next, we identified key pathways and biological processes that are dynamically regulated during terminal

granulopoiesis (Fig. 2l and Extended Data Fig. 4l). Specification and commitment are accompanied by distinct biological processes inducing withdrawal from the cell-cycle, a general collapse of gene expression concurrent with the sequential induction of innate immune effector gene expression (Fig. 2l).

## Mutation impacts cell states differently

Given references for granulopoietic genomic states, we could now determine the transcriptional deregulation underlying the *Gfi1*<sup>R412X/-</sup> defects in neutrophil production and function. We extended CITE-Seq and complementary Fluidigm captures to *Gfi1*<sup>+/-</sup> and *Gfi1*<sup>R412X/-</sup> GMP (Extended Data Fig. 4b, see online viewer<sup>3</sup>, Extended Data Fig. 6a–k, 7a–d, and <sup>20</sup>). Next, we applied a computational workflow (cellHarmony<sup>4</sup> Extended Data Fig. 6b) to assign Gfi1-mutant cells to ICGS clusters and determine differential gene expression. Most *Gfi1*<sup>R412X/-</sup> GMP are monocytic progenitors (51% by CITE-Seq, 55% by Fluidigm), a ~3 fold increase relative to *Gfi1*<sup>+/-</sup> or *Gfi1*<sup>+/+</sup>. Few cells were assigned beyond proNeu-1 (6.5 fold decrease)(Extended Data Fig. 6c, d, 7b, c). However, capturing rare *Gfi1*<sup>R412X/-</sup> CD11b<sup>high</sup> GMP-P (Extended Data Fig. 6a) revealed cells within each of the granulocytic clusters (Extended Data Fig. 6c–e, 7b, c) resembled that of the wild-type (Extended Data Fig. 4c), including known myeloid, cell cycle, and surface marker genes (Extended Data Fig. 6f). Strikingly, of Gfi1 targets defined by ChIP-Seq<sup>20</sup> (57% of differentially expressed genes), only a minority are disrupted across all clusters (see *Gfi1*, *Mpo*, *Irf8* and *Mmp8* expression in Extended Data Fig. 6f). Instead, using either 10x or Fluidigm technology most deregulated expression occurs during specification or in specific clusters (Fig. 3a, Extended Data Fig. 6k).

To understand the underlying gene regulatory mechanisms, we performed scATAC-Seq on *Gfi1*<sup>+/+</sup> and *Gfi1*<sup>R412X/R412X</sup> Modified-GMP-gate cells (Extended Data Fig. 7e–j). The scATAC-Seq clusters were aligned to CITE-Seq cell populations (Extended Data Fig. 7e, f) using label transfer in Seurat<sup>35</sup> (consistent with SNAP-ATAC<sup>28</sup>; see Extended Data Fig. 7i), and cluster-specific ATAC-peaks were associated with lineage-specific genes and sequential neutrophil programming (Extended Data Fig. 7k, Supplementary Information: UCSC Genome Browser Session to Visualize ChIP-Seq and scATAC-Seq Data). We computed differentially accessible loci (cicero gene-activity scores), identified regions correlated or anticorrelated with differential gene expression (Fig. 3b), and inferred dynamic transcription factor activity changes (Extended Data Fig. 7l). Accessible DNA in *Gfi1*<sup>R412X/R412X</sup> clusters were differentially enriched for Gfi1 and Irf8 motifs; suggesting the failure of Gfi1-R412X to silence them. Notably, zinc-finger 6 is dispensable for DNA binding *in vitro*<sup>29</sup>, which we confirmed for Gfi1-R412X (Extended Data Fig. 8a–e). Moreover, *Gfi1*<sup>R412X/R412X</sup> ChIP-Seq on sorted GMP revealed most loci normally bound by Gfi1 (Extended Data Fig. 8f). However, while Gfi1-target loci demonstrate dynamic chromatin accessibility in wild-type cells (Fig. 3c, left), these patterns are disrupted in *Gfi1*<sup>R412X/R412X</sup> cells, including *Irf8* (Fig. 3c, right, Fig. 3d, Extended Data Fig. 8g–l). Thus, Gfi1-R412X occupancy is not associated with normal dynamic regulation of chromatin accessibility.

We noted Gfi1-R412X deregulation of both *Irf8* expression and Gfi1-bound chromatin accessibility (Fig. 3a, c, d, Extended Data Fig. 6f, k), so we limited *Irf8* alleles. Similar to

*Gfi1<sup>R412X/R412X</sup>* which repressed *Irf8*-GFP expression and partially rescued granulopoietic specification (Fig. 1i, Extended Data Fig. 9a–f), *Gfi1<sup>R412X/-</sup>Irf8<sup>+/-</sup>* induces a partial rescue of neutrophil production (Fig. 3e, Extended Data Fig. 9a–d). However, *Gfi1<sup>R412X/R412X</sup>* and *Gfi1<sup>R412X/-</sup>Irf8<sup>+/-</sup>* neutrophils still exhibit abnormal morphologies (Fig. 1c, j, Fig. 3e).

## Rescuing neutropenia but not function

To determine the genes underlying genetic rescue, we extended Fluidigm captures to genetically-rescued GMP-gate cells (Extended Data Fig. 4b, 9g–l) and CITE-Seq of Modified-GMP-gate cells to all mice (Fig. 4a–f, Extended Data Fig. 5c, 7b, d). Joint embedding of CITE-Seq datasets into a single Uniform Manifold Approximation and Projection (UMAP) reveals similar embedding of cell populations in *Gfi1<sup>+/+</sup>*, *Gfi1<sup>+/-</sup>*, and *Gfi1<sup>K403R/-</sup>* mice. All *Gfi1*-R412X mutants display a dramatically altered trajectory (Fig. 4b), but genetic rescue increased the fraction of granulocytic specifying cells (Fig. 4b, Extended Data Fig. 7b, 9j). Similarly, ADT expression was only subtly different between *Gfi1<sup>+/+</sup>*, *Gfi1<sup>+/-</sup>*, and *Gfi1<sup>K403R/-</sup>*; however, *Gfi1<sup>R412X/-</sup>* and genetic rescues showed modest but consistent ADT perturbation in Ly6g, CD55, CD106, CD115 and F4/80 (Fig. 4a, Extended Data Fig. 7b, d).

Using cluster-specific comparisons between groups in both datasets, we identified those genes transcriptionally repaired by both genetic rescues (Fig. 4c, Extended Data Fig. 9k) and those that are not repaired by either genetic rescue (Fig. 4d, Extended Data Fig. 9l). Notably, processes controlling neutrophil chemotaxis, NADPH oxidation, defense response, translation, and chromosome condensation were not repaired (Fig. 4f, Extended Data Fig. 9l). Indeed, *Gfi1*-R412X mutant neutrophils failed to condense their chromatin (Fig. 1c, j, Fig. 3e).

Next, we captured SCN-patient and age-matched-donor neutrophils (Fluidigm C1v4; Extended Data Fig. 10, Supplementary Information). Differentially expressed genes are dynamically expressed during normal murine granulopoiesis (Fig. 4g), and enriched for many of the same *Gfi1*-ZnF6-dependent biological processes (e.g., translation, neutrophil chemotaxis and defense response)(Fig. 4h).

To validate defects in translation, we performed SWATH<sup>30</sup> proteomic analysis on purified bone marrow neutrophils. Dissimilar to their elevated gene expression (Extended Data Fig. 6f), we find loss of neutrophil granule protein expression (e.g. *Camp*, *Mmp8*, and *Mmp9*) in all *Gfi1*-mutant neutrophils (Fig. 4i). In addition, NADPH oxidase complex proteins were low (Fig. 4i), which manifested as a blunted oxidative burst response *in vitro* (Fig. 4j). SCN patients display innate immune defects in spite of G-CSF therapy,<sup>31</sup> and their neutrophils exhibit deregulated genes involved in innate immune functions (Fig. 4h) suggesting that their cytokine-rescued neutrophils may be functionally defective. Similar to *Gfi1*-mutant murine neutrophils (which are also produced under conditions of high G-CSF, Extended Data Fig. 3b), we found that SCN-patient peripheral blood neutrophils exhibited a blunted oxidative burst response (Fig. 4k). Our findings provide evidence that genetic or cytokine rescue of granulocyte specification is not sufficient to rescue post-commitment innate effector programs.

## Discussion

Delineating disease-associated genetic variation is the focus of intensive research; however, determining which sequence alterations are pathogenic requires generating and analyzing genetic models. Exploiting models to resolve the pathobiological impact of mutations is limited by both technology and our understanding of normal biology. We describe a transferable workflow that can be harnessed to answer developmental questions across disciplines. Our results suggest that such analyses can reveal cell-state-specific impacts of mutations (likely due to accompanying changes in the composition of transcription factors and chromatin accessibility at their target genes), with direct consequences for attempts to repair defects. We think that this finding has significant implications for the study of congenital and acquired genetic changes; especially cancers which are multiclonal. Moreover, this approach could be extended to the analysis of the therapeutic impact of new small molecules, where bulk cell analyses or current single cell analytic pipelines might gloss over rare but important cell states.

## Methods

No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were blinded to allocation for *C. albicans* and *S. aureus* experiments.

### Human Samples.

De-identified clinical data and peripheral blood from healthy donors or neutropenic patients was obtained at Cincinnati Children's Hospital Medical Center through informed consent under an approved institutional review board research protocol.

### Mice.

*Irf8<sup>GFP1</sup>*, *Gfi1<sup>ex2-3/ex2-3 2</sup>*, *Rosa26<sup>Fucci2 3</sup>*, and *Irf8<sup>m1.2Hm/J 4</sup>* mice were maintained on a C57BL/6 background, and *Ptprc<sup>a</sup>* (BoyJ) mice were purchased from Jackson Laboratories. Mice were maintained under specific pathogen-free conditions by Cincinnati Children's Hospital Medical Center (CCHMC) Veterinary Services and all procedures were approved by the Children's Hospital Research Foundation Institutional Animal Care and Use Committee (Protocol Number IACUC2017-0021).

To generate *Gfi1<sup>N382S</sup>*, *Gfi1<sup>K403R</sup>*, and *Gfi1<sup>R412X</sup>* mice, two pairs of ZFN RNAs that recognize target sites flanking *Gfi1* coding exon 6 were designed and generated by Millipore-Sigma (Genome Editing division). mRNAs encoding site-specific ZFNs (50ng/μl) were introduced into 1-cell mouse oocytes by standard pronuclear injection approach, and injected oocytes were transferred to a pseudo pregnant surrogate mother. To introduce specific mutations, oocytes were co-injected with ZFN mRNAs as well as a homologous donor construct (2ng/ml) containing the R412X mutation. Positive founder pups were identified using mutation-specific primers and mated to C57BL/6 mice to generate stable heritable knock-in lines. Constructs consisted of 1.5kb 5' and 0.8kb 3' arms of homology flanking the mutant *Gfi1* exon 6. The ZFN target sequences used were:

5'-GTCCCCTTCACCTTCCTTcccggaGCTGCTGGAGGAGATGAA-3' and

5'-CGTTGCGACCCACATGCTCTtgctaaCAGCTGGCTAAG-3', where the capital letters denote nucleotides actually bound by right and left ZFN proteins. Positive founders and subsequent progeny were genotyped by PCR using the primers: 5'-CAGAAAGCACACAGGCTTCA-3' and 5'-GATGAGCTTTGCACACTGGA-3' then subsequent restriction enzyme digestion using BamHI for *Gfi1*<sup>N382S</sup>, KpnI for *Gfi1*<sup>K403R</sup>, and EcoRI for *Gfi1*<sup>R412X</sup>. Expression of the mutant alleles was confirmed by TOPO cloning/ TOP10 transformation (Thermo Fisher) of RT-PCR products generated using the same primers that were used for genotyping, followed by Sanger sequencing of individual clones with T3 and T7 primers and analysis using ApE (version 2.0.49.0).

### Flow cytometry and cell sorting.

Mice were euthanized using carbon dioxide followed by cervical dislocation. Peripheral blood was collected into EDTA-coated tubes, and hind limb bones (femurs, tibiae, and the iliac crest) were harvested immediately after euthanasia and stored in cold FACS buffer (1% FBS, 0.01% NaN<sub>3</sub> in DPBS) under sterile conditions. Bones were flushed using a syringe for transplantation or crushed using a mortar and pestle for all other applications, then passed through a 40 µm cell strainer (Becton, Dickinson and Company) to obtain single cell suspensions for downstream applications. Prior to analytical flow cytometry, erythrocytes were lysed using ACK buffer (Gibco), then cells were washed in FACS Buffer and resuspended in FACS Buffer containing DAPI (Thermo Fisher) or 7-AAD (Becton, Dickinson, and Company). Flow cytometry analyses were conducted on a FACS LSR II or FACS LSRFortessa (Becton, Dickinson, and Company) and analyzed using FlowJo software (FlowJo, Ashland, OR, USA).

To enrich for murine stem/progenitor populations, freshly isolated bone marrow cells were incubated with CD117 Microbeads or with components of the Mouse Lineage Depletion kit and separated on an AutoMACS Pro separator (Miltenyi) according to manufacturer specifications. Alternatively, murine LSK cells were purified by first using the Sca-1 Multisort Kit (Miltenyi) for separation on an AutoMACS Pro separator then cells were subsequently incubated with CD117 Microbeads and separated again on an AutoMACS Pro separator. Murine bone marrow neutrophils were isolated using the EasySep™ Mouse Neutrophil Enrichment Kit (Stem Cell Technologies) according to manufacturer's specifications. Human peripheral blood neutrophils were enriched from whole blood using the EasySep™ Direct Human Neutrophil Isolation Kit (Stemcell Technologies) according to manufacturer's specifications.

Peripheral blood analysis: Peripheral blood cells were stained in FACS buffer with a mix of antibodies: CD16/CD32 (clone 2.4G2, Becton, Dickinson and Company), CD3-APC (clone 145-2C11, Becton, Dickinson and Company), CD45R-PE (clone RA3-6B2, Becton, Dickinson and Company), CD11b-PacificBlue (clone M1/70, BioLegend), and Ly6g-PerCP-Cy5.5 (clone 1A8, BioLegend). For analysis of transplant chimerism, cells were also stained with CD45.1-BV605 (clone A20, Biolegend) and CD45.2-AlexaFluor700 (clone 104, Biolegend). To quantify neonatal murine blood numbers, samples were supplemented with 5.24 µm AccuCount blank particles (Spherotech, Lake Forest, IL, USA) immediately prior



to analysis. To purify peripheral blood neutrophils for cytospin analysis, cell sorting was performed on a FACSaria II (Becton, Dickinson, and Company) and cells were collected in a solution of DPBS + 50% FBS (Atlanta Biologicals).

Mature myeloid bone marrow analysis: Whole bone marrow cells were stained in FACS buffer with a mix of antibodies: CD16/CD32 (clone 2.4G2, Becton, Dickinson and Company), and Ly-6B.2-AlexaFluor647 (clone 7/4, Bio-Rad), F4-80-AlexaFluor488 (clone Cl:A3-1, Bio-Rad) for 30 minutes on ice.

Hematopoietic stem cell analysis: Whole bone marrow cells were stained for 30 minutes on ice with a cocktail of antibodies: Fc Block (Becton, Dickinson, and Company), biotin-conjugated anti-CD3e (clone 145-2C11, BioLegend), biotin-conjugated anti-CD4 (clone RM4-5, Thermo Fisher), biotin-conjugated anti-CD8 (clone 53-6.7), biotin-conjugated anti-CD11b (clone M1/70, Becton, Dickinson, and Company), biotin-conjugated anti-CD19 (clone 6.D5, BioLegend), biotin-conjugated anti-CD127 (clone B12-1, Becton, Dickinson, and Company), biotin-conjugated anti-B220 (clone RA3-6B2, BioLegend), biotin-conjugated anti-Gr1 (clone RB6-8C5, Becton, Dickinson, and Company), and biotin-conjugated anti-Ter119 (clone TER-119, BioLegend). Cells were then washed twice with FACS buffer and incubated on ice overnight with a cocktail of antibodies; streptavidin-APC-Cy7 (Becton, Dickinson, and Company), APC-conjugated anti-CD117 (clone 2B8, BioLegend), PE-Cy7-conjugated anti-Sca-1 (clone D7, Becton, Dickinson, and Company), FITC-conjugated anti-CD34 (clone RAM34, Becton, Dickinson, and Company), PacificBlue-conjugated anti-CD48 (clone HM48-1, BioLegend), PE-conjugated anti-CD135 (clone A2F10, BioLegend) and Brilliant Violet 510-conjugated anti-CD150 (clone TC15-12F12.2, BioLegend).

Myeloid progenitor analysis: Prior to FACS sorting, Miltenyi AutoMacs CD117-enriched bone marrow cells were stained for 1 hour at room temperature protected from light with a mix of antibodies: PerCP-eFluor710-conjugated anti-CD16/CD32 (clone 93, Thermo Fisher), biotin-conjugated anti-CD3e (clone 145-2C11, BioLegend), biotin-conjugated anti-CD4 (clone RM4-5, Thermo Fisher), biotin-conjugated anti-CD8 (clone 53-6.7), biotin-conjugated anti-CD11b (clone M1/70, Becton, Dickinson, and Company), biotin-conjugated anti-CD19 (clone 6.D5, BioLegend), biotin-conjugated anti-CD127 (clone B12-1, Becton, Dickinson, and Company), biotin-conjugated anti-B220 (clone RA3-6B2, BioLegend), biotin-conjugated anti-Gr1 (clone RB6-8C5, Becton, Dickinson, and Company), and biotin-conjugated anti-Ter119 (clone TER-119, BioLegend), Brilliant Violet 421-conjugated anti-CD34 (clone RAM34, Becton, Dickinson and Company), APC-conjugated anti-CD117 (clone 2B8, BioLegend), and PE-Cy7-conjugated anti-Sca-1 (clone D7, Becton, Dickinson, and Company). Cells were then washed twice with FACS buffer and incubated for 15 minutes at room temperature with streptavidin-APC-Cy7 (Becton, Dickinson, and Company). Cells were washed once in FACS Buffer, and resuspended in FACS Buffer for cell sorting. Cell sorting was performed on a FACSaria II (Becton, Dickinson, and Company) and cells were collected in a solution of DPBS + 50% FBS (Atlanta Biologicals).

**Myeloid progenitor and precursor gate (GMP-P):**

Prior to FACS sorting, CD117-enriched bone marrow cells were stained for 1 hour at room temperature protected from light with a mix of antibodies: PerCP-eFluor710-conjugated anti-CD16/CD32 (clone 93, Thermo Fisher), biotin-conjugated anti-CD3e (clone 145-2C11, BioLegend), biotin-conjugated anti-CD4 (clone RM4-5, Thermo Fisher), biotin-conjugated anti-CD8 (clone 53-6.7), biotin-conjugated anti-CD19 (clone 6.D5, BioLegend), biotin-conjugated anti-CD127 (clone B12-1, Becton, Dickinson, and Company), biotin-conjugated anti-B220 (clone RA3-6B2, BioLegend), biotin-conjugated anti-Ter119 (clone TER-119, BioLegend), AlexaFluor700-conjugated anti-CD11b (clone M1/70, BioLegend), Brilliant Violet 785-conjugated anti-Ly6c (clone HK1.4, BioLegend), FITC-conjugated anti-Ly6g (clone 1A8, BioLegend), Brilliant Violet 421-conjugated anti-CD34 (clone RAM34, Becton, Dickinson and Company), APC-conjugated anti-CD117 (clone 2B8, BioLegend), and Brilliant Violet 605-conjugated anti-CD115 (clone T38-320, Becton, Dickinson, and Company). Cells were then washed twice with FACS buffer and incubated for 15 minutes at room temperature with streptavidin-APC-Cy7 (Becton, Dickinson, and Company). Cells were washed once in FACS Buffer, and resuspended in FACS Buffer for cell sorting. Cell sorting was performed on a FACSAria II (Becton, Dickinson, and Company) and cells were collected in a solution of DPBS + 50% FBS (Atlanta Biologicals).

**Alternate GMP-P gate (incorporating additional markers):**

Alternatively, prior to analysis, CD117-enriched bone marrow cells were stained for 1 hour at room temperature protected from light with a mix of antibodies: Brilliant UV 395-conjugated anti-CD16/CD32 (clone 93, Becton, Dickinson, and Company), biotin-conjugated anti-CD3e (clone 145-2C11, BioLegend), biotin-conjugated anti-CD4 (clone RM4-5, Thermo Fisher), biotin-conjugated anti-CD8 (clone 53-6.7), biotin-conjugated anti-CD19 (clone 6.D5, BioLegend), biotin-conjugated anti-CD127 (clone B12-1, Becton, Dickinson, and Company), biotin-conjugated anti-B220 (clone RA3-6B2, BioLegend), biotin-conjugated anti-Ter119 (clone TER-119, BioLegend), PE-Cy7-conjugated anti-CD11b (clone M1/70, BioLegend), Brilliant Violet 785-conjugated anti-Ly6c (clone HK1.4, BioLegend), PerCP-Cy5.5-conjugated anti-Ly6g (clone 1A8, BioLegend), Brilliant Violet 421-conjugated anti-CD34 (clone RAM34, Becton, Dickinson and Company), Brilliant Violet 650-conjugated anti-CD117 (clone 2B8, BioLegend), and Brilliant Violet 605-conjugated anti-CD115 (clone T38-320, Becton, Dickinson, and Company). Additional analyses were performed by also individually staining cells with the following antibodies: PE-conjugated anti-CD18 (clone M18/2, BioLegend), PE-conjugated anti-CD27 (clone LG.3A10, BioLegend), PE-conjugated anti-CD55 (clone RIKO-3, BioLegend), PE-conjugated anti-CD84 (clone mCD84.7, BioLegend), Alexa Fluor 700-conjugated anti-CD177 (clone 1171A, R&D Systems, Minneapolis, MN, USA), PE-conjugated anti-CD106 (Vcam1, clone 429, BioLegend), PE-conjugated anti-CD217 (IL-17R, clone PAJ-17R, Thermo Fisher). Cells were then washed twice with FACS buffer and incubated for 15 minutes at room temperature with streptavidin-APC-Cy7 (Becton, Dickinson, and Company).

### Cell Culture and viral transduction.

Lentiviral particles were generated as described previously<sup>5</sup>. Briefly, Lenti-X 293T cells (Clontech) were seeded one day prior to transfection with individual expression vectors (pLVX-EF1 $\alpha$ -IRES-Puro base vector, Clontech), the lentiviral packaging plasmid 8.9, and envelope plasmid VSV-G using Transit-LT1 (Mirus) according to manufacturer instructions. Growth medium was changed the following day. Virus-containing supernatant was collected 48 and 72 hours post-transfection, pooled and concentrated via ultracentrifugation over a 20% sucrose cushion, then aliquoted and frozen at  $-80^{\circ}\text{C}$ .

Freshly isolated murine LSK bone marrow cells were cultured in IMDM (ThermoFisher Scientific) supplemented with 100U/mL Penicillin-Streptomycin (ThermoFisher Scientific), 10% BIT (Stemcell Technologies), 20 ng/mL IL-3, 20 ng/mL IL-6, and 50 ng/mL SCF (Miltenyi) with lentiviral particles overnight at  $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$ . Media was changed and supplemented with 1.5  $\mu\text{g}/\text{mL}$  puromycin (Invivogen, San Diego, CA, USA) 48 hours after transduction, and the Irf8-GFP levels were determined by FACS 72 hours later.

### RNAscope Imaging.

Human CD34<sup>+</sup> cells were isolated from either G-CSF mobilized peripheral blood or fresh bone marrow aspirate using CliniMACS<sup>®</sup> CD34<sup>+</sup> (Miltenyi, Cat. No. 130-017-501) or FACS sorting. Cells were fixed with 4% neutral buffered formalin at  $37^{\circ}\text{C}$  for 1 hour and cyto-centrifuged onto SuperFrost Plus<sup>®</sup> Slides (Fisher Scientific, Cat. No. 12-550-15). Samples were then processed according to the RNAscope<sup>®</sup> V2 User Manual, (ACDBio). Channel 1 of the 3-plex Negative Control Probe (ACDBio, Cat. No. 320871), probing for the bacterial gene *dabB*, was developed to determine background fluorescence. Negligible fluorescent signal was generated by this probe in all samples. Channel 1 of experimental probes for *POLR2A* intron 1 (ACDBio, Cat. No. 588751), *GFI1* intron 3 (ACDBio, Cat. No. 575371), and *GFI1* intron 6 (ACDBio, Cat. No. 588761) was also developed. Samples were stained using the Opal<sup>™</sup> 570 reagent (Perkin Elmer, Cat. No. FP1488001KT) at a dilution of 1:1500. Slides were imaged with a Nikon A1 confocal on an Eclipse TiE inverted microscope with a 60X Plan Apo IR DIC-Water Immersion objective. Z-stacks were acquired with a 0.11  $\mu\text{m}$  pixel size and 0.25  $\mu\text{m}$  Z interval. Z-stacked data were analyzed using Imaris 9 with transcripts per cell defined using “spot” detection. Transcripts per cell were quantified using Imaris XT MatLab algorithms. Cells with no transcripts were excluded from final analysis. Images shown are maximum intensity projections of Z-stacks.

### GFI1-R412X iPSC generation and differentiation.

iPSC lines were generated as described previously<sup>6</sup>. CRISPR-Cas9 was used to introduce the R412X mutation to the *GFI1* locus of an iPSC line (iPSC286C11) derived from a healthy individual. A guide RNA targeting the last intron of *GFI1* (5'-GTGACTCCGTTCTAATTCAG-3') was designed according to the web tool (<http://CRISPOR.org>) and cloned into a modified pX458 vector (Addgene #48138) that expresses an optimized sgRNA scaffold and a high-fidelity eSpCas9(1.1)-2A-GFP. The editing activity of the plasmid was validated in HEK293T cells by T7E1 assay. The donor plasmid was constructed by inserting the DNA fragments containing desired mutations and homologous arms to a pUC57 vector carrying a loxP-flanked EF1 $\alpha$ -GFP-2A-Puro cassette<sup>6</sup>. For gene

editing, a single cell suspension of iPSC286C11 cells was prepared using accutase and  $0.75 \times 10^6$  cells were reverse-transfected in a 12-well matrigel-coated dish with 0.6  $\mu\text{g}$  of the gRNA-containing pX458 vector, 0.6  $\mu\text{g}$  of donor plasmid, and 0.18  $\mu\text{g}$  of pRetroSuper-p53sh (a kind gift from Dr. Jim Mulloy) using the manufacturer's recommended protocol (TransIT-LT1; Mirus). One day post-transfection, mTeSR1 containing 1  $\mu\text{g}/\text{mL}$  puromycin was added to cells for 48 hours to eliminate non-transfected cells. Five days post-transfection, a single cell suspension of surviving cells was prepared using accutase. Cells were replated at  $0.25 \times 10^6$  per well in a matrigel-coated 6-well dish and cultured for 4 days in mTeSR1 containing 10% CloneR (StemCell Technologies), using the manufacturer's recommended protocol. Cells were subsequently fed daily with mTeSR1 containing 1  $\mu\text{g}/\text{mL}$  puromycin for an additional 1–2 weeks before colonies with stereotypical iPSC morphology were manually excised and expanded for genotyping. Correctly targeted clones were identified by PCR, enzyme digestion and Sanger Sequencing and confirmed to have normal karyotype. To remove the loxP-flanked EF1a-GFP-2a-Puro cassette, cells were incubated with TAT-CRE recombinase according to manufacturer's recommendations (Millipore Sigma). GFP<sup>-</sup> cells were subsequently purified by FACS sorting.

Granulocytes were generated from iPSC using a three-step differentiation process. First, CD34<sup>+</sup>/CD45<sup>+</sup> hematopoietic progenitors were derived using the STEMdiff hematopoietic kit (Stem Cell Technologies, Vancouver, BC). Floating CD34<sup>+</sup>/CD45<sup>+</sup> cells were harvested and cultured in RPMI 1640 medium (Gibco) containing 10% FBS (Hyclone), 50 ng/mL SCF, 10 ng/mL IL-3 and 10 ng/mL GM-CSF (Peprotech) and cultured for 5 days. After 5 days, culture medium was transitioned to RPMI 1640 medium supplemented with 10% FBS and 50 ng/ml G-CSF (Peprotech) and cultured for another 5 days. Cells were stained with PE-conjugated anti-CD45 (clone HI30, Becton, Dickenson, and Company), APC-conjugated anti-CD34 (clone 581, Becton, Dickenson, and Company), APC-Cy7-conjugated anti-CD11B (clone ICRF44, Becton, Dickenson, and Company), Vioblue-conjugated anti-CD14 (clone REA599, Miltenyi), and PE-Cy7-conjugated anti-CD16 (clone REA423, Miltenyi) prior to FACS analysis. To analyze *GFI1* expression, cells were lysed in TriZol (Thermo Fisher) and total RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Amplification of cDNA was performed using GoTaq Green Master Mix (Promega) using 5'-CAGGAACGGAGCTTTGACTG-3' and 5'-GAAGGAGGAGCAACCTGGTA-3' primers prior to sequencing using 5'-CAAGAGGTCATCCACACTGTC-3' or 5'-TCTGGAAAGTCAGAAGGGAGT-3' primers.

### Immunoblot analysis.

Freshly isolated Lineage<sup>Neg</sup> bone marrow cells were lysed in laemmli buffer, briefly sonicated, and boiled at 100°C for 5 minutes before being subjected to SDS-PAGE. The resolved proteins were transferred onto nitrocellulose membranes (GE Healthcare) that were subsequently blocked in 5% nonfat dried milk (Carnation) in TBS-T (0.1% Tween 20, Sigma Aldrich) for 1 hour at room temperature with agitation. Following washing with TBS-T, membranes were incubated overnight at 4°C with agitation in a solution of 5% BSA Fraction V/TBS-T (Fisher Scientific) containing goat anti-Gfi1 (R&D Systems) antibody diluted at 1:1,000. Following a wash with TBS-T, membranes were incubated for 2 hours at room temperature with agitation in a solution of 2% nonfat dried milk in TBS-T containing a

1:5,000 dilution of HRP-conjugated anti-goat secondary antibody (Invitrogen). Following three washes with TBS-T, chemiluminescent detection of blotted proteins was performed using ECL (Thermo Fisher) and detected using X-ray film (Lab Scientific). Next, membranes were washed thoroughly in TBS-T, then stripped in Restore Plus (Thermo Fisher) for 10 minutes at room temperature with agitation. After washing in TBS-T, membranes were blocked as before, and incubated as described above with a 1:5,000 dilution of mouse anti- $\beta$ -Actin (Sigma Aldrich) and then a 1:10,000 dilution of HRP-conjugated anti-mouse secondary antibody (GE Healthcare) before chemiluminescent detection was achieved as before.

### **Cytospin.**

Freshly prepared cells were diluted in 200  $\mu$ L of FACS buffer and spun onto VWR VistaVision Histobond slides (VWR) for 3 minutes at 900 rpm using a Cytospin 4 apparatus (Thermo Scientific). Slides were then fixed and stained using the Camco stain pak (Cambridge Diagnostic Products, Inc), and once dry, sealed using Cytoseal 60 (Thermo Scientific) and microscope cover glass (Globe Scientific Inc.).

### **Colony forming unit assays.**

Freshly isolated Lineage<sup>Neg</sup> or c-Kit<sup>+</sup> cells were plated at 1,000 cells/mL in M3434 (Stemcell Technologies) and the differential colony number was determined 7 days later.

### **Bone marrow transplantation.**

A single cell suspension of  $1 \times 10^6$  unfractionated bone marrow cells from 6-week old mice (CD45.2) was injected into lethally irradiated (11.75 Gy) CD45.1 congenic recipients.

### **Code availability.**


All described code is provided in Github (<https://github.com/nsalomonis/altanalyze>).

### **Data availability.**

scRNA-Seq, CITE-Seq, scATAC-Seq, and ChIP-Seq data is deposited as GEO SuperSeries GSE120409 and in Synapse (<https://www.synapse.org/#!Synapse:syn16806696>).

Proteomic data are available via ProteomeXchange ([www.ebi.ac.uk/pride/archive/](http://www.ebi.ac.uk/pride/archive/)) with identifier PXD010943. Extensive processed and primary data are provided and organized in Synapse, including 10x Genomics count matrices, Fluidigm expression, single-cell populations, quality control metrics, 10x Genomics Cell Ranger outputs (summary report, loupe browser files), genomic coordinate peak files and differential expression results (cellHarmony).


Extended Data



Extended Data Figure 1. Functional assessment of SCN patient-derived GFII1 variants and generation of Gfi1 ZnF-mutant mice.

**a**, Representative FACS plots of lentiviral transduced LSK cells isolated from adult *Irf8-eGFP* transgenic mice with the %Irf8-eGFP<sup>high</sup> indicated. **b**, Graphical summary of FACS analysis of lentiviral transduced LSK cells isolated from adult *Irf8-eGFP* transgenic mice (top) with locations of the variants mapped to the GFII1 protein (bottom). EV; empty vector, \*P2A; mutation not found in patients, italics; other variants detected in the same patient,

bold; also found in patients diagnosed with a malignancy, ATG; start codon, TGA; stop codon, gray blocks; characterized protein domains, SNAG; Snail/Gfi1 family domain, SUMO; sumoylation domain, ZnF; zinc-finger. **c**, Schematic of the *Gfi1* locus annotated with relevant features. Line with small arrows; intronic regions, numbered blocks; exons, black blocks; coding regions, gray blocks; noncoding regions, ATG; start codon, TGA; stop codon, SNAG; Snail/Gfi1 family domain-encoding region, ZFN; zinc-finger nucleases, large arrows; noncoding region used for genotyping. **d-f**, Schematic of the nucleotide changes made to the coding region and 3' UTR to introduce the **d**, **d'** N382S, **e**, **e'** K403R, and **f**, **f'** R412X mutations. **g**, Representative genotyping of the ZnF-mutant mice with or without restriction enzyme digestion. **h**, Representation of Sanger sequencing analysis of cDNA from adult whole bone marrow. Targeted wild-type nucleotides are underlined, mutated nucleotides are in bold, and red nucleotides indicate the location of the stop codon. **i**, Immunoblot analysis of two R412X founder lines using adult murine Lineage<sup>Neg</sup> bone marrow lysates. **j**, Graphical summary of FACS analysis of neonatal murine peripheral blood. **k**, Total cell counts per mL of neonatal peripheral blood as determined by FACS. **l**, Representative RNAscope images (left) and transcript quantitation (right) of the indicated transcripts in primary human CD34+ cells. The number of cells scored (left) and the number of donors tested (right) is indicated. **m**, Representative electropherogram plots from Sanger sequencing of *GFI1* RT-PCR products derived from iPSC. The arrow indicates the nucleotide substitution made to introduce the R412X mutation. **n**, Representative FACS plots of iPSC cells at the end of the 10-day hematopoietic differentiation protocol. **o**, Representative cytospin images of iPSC-derived neutrophils. Data in **a**, **b**, and **l** are representative of three biological replicates, data in **j** and **k** are representative of individual biological replicates, and is plotted as mean in **a** or as mean  $\pm$  s.e.m in **b**, **j**, **k**, and **l**. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$  as determined by two-tailed *t*-test. Data in **i** displays two biological replicates for each founder line. Data in **m-o** are representative of two independent experiments. Scale bars in **l** represent 2  $\mu$ m and 10  $\mu$ m in **o**.




**Extended Data Figure 2. Characterization of *Gfi1* ZnF-mutant mice at steady-state.**

**a**, Graphical representation of FACS analysis of adult murine peripheral blood. **b**, FACS plots and graphical representation of FACS analysis of adult murine peripheral blood. **c**, Graphical summary of colony-forming-unit (CFU) assays performed on adult Lineage<sup>Neg</sup> bone marrow cells from two different founder lines. G; granulocyte, M; monocyte, GM; granulocyte-monocyte, BFU-E; burst-forming-unit erythroid, GEMM; granulocyte, erythrocyte, monocyte, megakaryocyte. **d**, Total cell counts of adult murine whole bone marrow harvested from two femurs and tibias per mouse. **e**, FACS plots and quantitation of



adult murine bone marrow populations. **f**, Representative cytopins of adult murine whole bone marrow. Data in **f** are representative of three biological replicates, and the scale bar represents 10  $\mu$ m. Data in **a-e** are displayed as mean  $\pm$  s.e.m. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , and \*\*\*\*  $p < 0.0001$  as determined by two-tailed  $t$ -test.




**Extended Data Figure 3. Inflammatory-cytokine-independent emergency granulopoiesis and high G-CSF levels in *Gfi1* ZnF-mutant mice at steady-state and functional analysis of *Gfi1* ZnF-mutants.**

**a**, FACS plots and quantitation of adult murine Lineage<sup>Neg</sup>, c-Kit<sup>+</sup>, Sca-1<sup>+</sup> bone marrow cells. **b**, Quantitation of adult peripheral blood cytokine levels at steady-state by cytokine array. **c**, Quantitation of individual adult peripheral blood cytokine levels at steady-state by Luminex analysis. **d**, Survival analysis of lethally irradiated BoyJ recipients of adult whole bone marrow from adult Gfi1-mutant donors. **e**, Graphical representation of FACS analysis of peripheral blood chimerism in transplant recipients from **d** at 4 months post-transplant. **f-g**, Graphical representations of the total number of colonies in murine organs harvested at the indicated time points (see arrowheads in Fig. 1g, h) after infection with **f**, an LD<sub>50</sub> dose of *C. albicans* or **g**,  $5 \times 10^7$  CFU of *S. aureus*. **h**, Immunoblot analysis of adult murine Lineage<sup>Neg</sup> bone marrow lysates. Data in **a-c** and **e-g** are displayed as mean  $\pm$  s.e.m. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$  as determined by two-tailed *t*-test in **a-c** and **e-g**. \*\*  $p < 0.01$  as determined by two-sided Mantel-Cox test in **d**. Data in **h** are representative of 3 independent experiments.




gene. ICGS clusters are annotated (top). HSCP-1, haematopoietic stem cell progenitor; NK, natural killer T-cell progenitor; HSCP-2; Meg, megakaryocytic; Eryth, erythrocytic; DC, dendritic cell; MDP, monocyte dendritic cell progenitor; Multi-Lin\*, multi-lineage primed; cMoP, common monocyte progenitor; Mono, monocytic; MP, monocyte-committed progenitors; proNeu-1, neutrophil progenitor, proNeu-2; preNeu-1, neutrophil precursor, preNeu-2, preNeu-3; immNeu, immature neutrophil. **d**, Joint UMAP plot of scRNA-Seq data from **c** separated according to archival (<sup>29</sup>) and new Fluidigm captures. **e**, Bar chart of the heatmap in **c** displaying the incidence and amplitude of selected genes. **f**, Heatmap of correlation between gene expression and each displayed cluster as generated by MarkerFinder (AltAnalyze software). **g**, FACS plots comparing expression of Ly6g with the indicated surface marker. FMO; fluorescence minus one control. **h**, Heatmap of cell cycle gene expression in ICGS-defined clusters in scRNA-Seq data ( $n = 509$  cells). Each column represents a single cell and each row represents a single gene. Gene expression clusters were generated in AltAnalyze and the ICGS clusters are annotated (top). FACS gates are annotated (bottom). LSK, Lineage<sup>Neg</sup> c-Kit<sup>+</sup> Sca-1<sup>+</sup>; CMP, common myeloid progenitor; GMP, granulocyte monocyte progenitor; LK CD34<sup>+</sup>, Lineage<sup>Neg</sup> c-Kit<sup>+</sup> Sca-1<sup>Neg</sup> CD34<sup>+</sup>; GMP-P CD11b<sup>+</sup>, granulocyte monocyte progenitor and precursor, GMP-P CD11b<sup>+</sup> Ly6g<sup>low</sup>, GMP-P CD11b<sup>+</sup> Ly6g<sup>high</sup>. Key genes are indicated (right). **i**, Scatter plot representation of scRNA-Seq data from **h** comparing the gene expression of G1 to S phase transition genes with G2 to M phase transition genes in each cell. Each point represents a single cell. **j**, Bar chart of the heatmap in **h**, displaying the incidence and amplitude of selected genes. **k**, Heatmap of correlation between gene expression and each displayed cluster as generated by MarkerFinder. **l**, Heatmap of enrichment for Gene Ontology biological processes enriched in the granulocytic clusters from the Fluidigm scRNA-Seq data from **c** with key processes indicated (right). **m**, Scatter plot representation of scRNA-Seq data from **c** where each point represents a single cell. Reads per cell indicate RSEM transcript aligned read counts for each cell library. Genes expressed per cell indicate the number of genes with a TPM>1 for each single-cell library. Data in **a** and **g** are representative of three biological replicates. Data in **f** and **k** display Pearson correlation values.



**Extended Data Figure 5. CITE-Seq analysis of steady-state terminal granulopoiesis.**

**a**, FACS plots demonstrating the gating strategy used for sorting. The population sorted for scRNA-Seq is indicated in red. **b**, Heatmap of gene expression for cellHarmony assigned cell populations from CITE-Seq 10x Genomics captures (male and female mice,  $n = 11,132$  cells) compared to ICGS-defined clusters from the Fluidigm scRNA-Seq data. *De novo* marker genes (MarkerFinder) for each assigned cluster from the 10x Genomics data are shown (top). Each column represents a single cell and each row represents a single gene. HSCP-1, haematopoietic stem cell progenitor; NK, natural killer T-cell progenitor; HSCP-2;

Meg, megakaryocytic; Eryth, erythrocytic; DC, dendritic cell; MDP, monocyte dendritic cell progenitor; Multi-Lin\*, multi-lineage primed; IG2, *Irf8*-expressing GMP subpopulation 2; cMoP, common monocyte progenitor; Mono, monocytic; MP, monocyte-committed progenitors; proNeu-1, neutrophil progenitor, proNeu-2; preNeu-1, neutrophil precursor, preNeu-2, preNeu-3; immNeu, immature neutrophil. The gender of the host mouse of each cellular barcode (bottom) and example MarkerFinder genes in common between Fluidigm and 10x Genomics data are indicated (right). **c**, Violin plots of the gene and read-level metrics for each of the indicated libraries. Dashed lines indicate mean, lower, and upper quartiles. Sample size ( $n = \#$  cells) displayed (top). **d**, Lineage-priming scores for monocytic and granulocytic specification. Scatter plot displaying assigned scores for cellHarmony-assigned neutrophil progenitors (proNeu-2), monocytic progenitors (Mono), bi-potential monocytic-granulocytic intermediates (IG2) and megakaryocyte progenitors (Meg) from **b** (see Online Methods). Each point represents a single cell. **e**, Heatmap of row normalized ADT UMI counts ( $\log_2$ , median subtracted) for each corresponding cell from **b**. **f**, Heatmap of cell cycle gene expression displaying the same cells as **b** and the same genes as Extended Data Fig. 4h. **g**, Scatter plot representation of scRNA-Seq data from **f** comparing the gene expression of G1 to S phase transition genes with G2 to M phase transition genes in each cell. Each point represents a single cell. **h**, Bar chart of the heatmap in **b**, displaying the incidence and amplitude of selected genes. **i**, Heatmap of correlation between gene expression and each displayed cluster as generated by the MarkerFinder feature of AltAnalyze. **j-k**, Plots of CITE-Seq ADT UMIs where grey indicates all captured cells and **j**, red indicates cells classified by ICGS clusters or **k**, the top 1% of UMIs expressing the indicated gene. **l**, UMAP of 15,968 cell-barcodes colored according to cellHarmony assigned cell populations (10x genomics reference) where each dot represents a single cell. Minor contaminant populations (<30 cells per cluster) were excluded. **m**, Heatmap of row normalized CLR-transformed ADT counts of the indicated cell surface proteins (left) displayed as an average of all cells in the indicated clusters (top). **n**, Correlation plots between ADT UMI counts and the expression of genes (cellular barcode normalized UMI counts) encoding the corresponding proteins detected via CITE-Seq. Each dot represents a single cell. Linear trend lines for all cells with RNA expression >0 are indicated by dotted red lines with corresponding coefficients of determination displayed. Data in **i** displays Pearson correlation values.




**Extended Data Figure 6. Fluidigm-based transcriptional analysis of *Gfi1*<sup>R412X</sup> cells.**

**a**, FACS plots of adult murine bone marrow (left) and representative cytopsin of FACS-sorted adult murine bone marrow (right). The populations sorted for scRNA-Seq are indicated in red. **b**, Schematic summary of the cellHarmony algorithm. **c**, cellHarmony-assigned ICGS states of combined wild-type and *Gfi1*<sup>R412X</sup> Fluidigm scRNA-Seq data (*n* = 624 cells, excluding cell-cycle genes). Each tick mark represents data from a single cell. Gene expression clusters were generated in AltAnalyze and the ICGS clusters are annotated (top) (see Extended Data Fig. 4c) HSCP-1, haematopoietic stem cell progenitor; NK, natural

killer T-cell progenitor; HSCP-2; Meg, megakaryocytic; Eryth, erythrocytic; DC, dendritic cell; MDP, monocyte dendritic cell progenitor; Multi-Lin\*, multi-lineage primed; cMoP, common monocyte progenitor; Mono, monocytic; MP, monocyte-committed progenitors; proNeu-1, neutrophil progenitor, proNeu-2; preNeu-1, neutrophil precursor, preNeu-2, preNeu-3; immNeu, immature neutrophil. FACS gates are annotated (right). GMP, granulocyte monocyte progenitor; GMP-P CD11b<sup>+</sup>, granulocyte monocyte progenitor and precursor. **d**, Population distribution of Fluidigm scRNA-Seq data from Extended Data Fig. 6c and Extended Data Fig. 4c. **e**, cellHarmony heatmap of wild-type aligned *Gfi1*<sup>R412X/-</sup> cell gene expression as ordered in **c** (dotted lines). Each column represents a single cell and each row represents a single gene from Extended Data Fig. 4c. The FACS gates and ICGS clusters are annotated (top) and gene clusters are indicated (left). **f**, Bar chart of the heatmap in **e**, displaying the incidence and amplitude for selected genes. Arrows indicate differential expression of the adjacent gene, as compared to wild-type. **g**, Heatmap of MarkerFinder cell population-specific genes expression from the Fluidigm scRNA-Seq data ( $n = 191$  cells) with enriched pathway associated genes (right) and statistically enriched Gene Ontology biological processes (left). **h-i**, Heatmap of **h**, wild-type-driven (same genes as in **g**) or **i**, *de novo* MarkerFinder genes for cellHarmony classified *Gfi1*<sup>R412X/-</sup> cell populations ( $n = 62$  cells) annotated with enriched pathway associated genes (right) and statistically enriched Gene Ontology biological processes (left). **j**, Representation of the scRNA-Seq data from **k** displaying the fold change in gene expression in *Gfi1*<sup>R412X/-</sup> compared to wild-type cells in the indicated clusters with the number of genes up- or down-regulated displayed. Each point represents a single gene. **k**, Heatmap of Fluidigm differentially expressed Gfi1-target genes (excluding cell-cycle genes) where each column represents a single cell and each row represents a single gene, with key genes (right) and enriched biological processes (left) indicated. Cytospin data in **a** are representative of two biological replicates. Data in **a** are displayed as mean  $\pm$  s.e.m. \*\*\*\*  $p < 0.0001$  as determined by two-tailed *t*-test in **a**.






**Extended Data Figure 7. Population analysis of 10x Genomics-based scRNA-Seq data and label transfer from CITE-Seq transcriptome to scATAC-Seq cells.**

**a.** Identification of additional cell populations from wild-type scRNA-Seq data (ICGS unsupervised analysis, male-female CITE-Seq datasets). UMAP projections of scRNA-Seq data where the cell barcodes within the outlined region (top) were analyzed for additional heterogeneity through a second ICGS analysis (bottom). **b.** Heatmaps of additional CITE-Seq captures with cell assignments from cellHarmony. cellHarmony classifications were derived using the refined cluster annotation assignments from Extended Data Fig. 6c and 7a.

Each panel displays a scRNA-Seq heatmap of MarkerFinder genes from the cellHarmony reference (top), where each column represents a single cell and each row represents a single gene. Those cell barcodes captured from an independent FACS sort of Ly6g<sup>high</sup>/CD11b<sup>high</sup> GMP-P cells are indicated by a black bar (middle). Relative expression of median normalized ADTs (right) are shown in the bottom heatmaps. **c**, Assigned cell-population frequencies for *Gfi1*<sup>+/-</sup> and *Gfi1*<sup>R412X/-</sup> CITE-Seq (Modified GMP gate) cells datasets from cellHarmony. **d**, Heatmaps of differential ADT expression compared to *Gfi1*<sup>+/-</sup> for the indicated markers (right). **e**, tSNE plot of CITE-Seq transcriptome for the *Gfi1*<sup>+/+</sup> sample. **f**, tSNE plot of scATAC-Seq for the *Gfi1*<sup>+/+</sup> sample. **g**, tSNE plot of CITE-Seq transcriptome for the *Gfi1*<sup>R412X/R412X</sup> sample. **h**, tSNE plot of scATAC-Seq for the *Gfi1*<sup>R412X/R412X</sup> sample. **i**, Comparison of Seurat transferred CITE-Seq labels to unsupervised scATAC-Seq cell population prediction methods (SNAP-ATAC) for *Gfi1*<sup>+/+</sup>. Percentage of overlapping cells for all pairwise comparisons between SNAP-ATAC clusters to CITE-Seq clusters derived from Seurat label transfer. **j**, Comparison of Seurat transferred CITE-Seq labels to unsupervised scATAC-Seq cell population prediction methods (SNAP-ATAC) for *Gfi1*<sup>R412X/R412X</sup>. Percentage of overlapping cells for all pairwise comparisons between SNAP-ATAC clusters to CITE-Seq clusters derived from Seurat label transfer. **k**, Cell-cluster combined scATAC-Seq marker peaks associated with *Gfi1*<sup>+/+</sup> CITE-Seq annotated cell populations (Seurat 3 label transfer using cicero gene activity scores). Each row is a cluster (left) and each column is a locus within 50 kb of a CITE-Seq marker gene for each cluster (bottom), where the colored bars represent the normalized read count coverage. **l**, Heatmaps of transcription factor (TF)-motif-enrichment probabilities (-log<sub>10</sub>) in accessible regions of *Gfi1*<sup>+/+</sup> (blue) or *Gfi1*<sup>R412X/R412X</sup> (red) cell populations (indicated left). Each row represents a TF motif from the Cisbp2 database (indicated right). Each dot in **a** and **e-h** represents a single cell barcode that is pseudo-colored for its ICGS predicted cluster.




locus. These loci contain a GFI1 ChIP-Seq peak and the corresponding genes are differentially expressed in *Gfi1*<sup>R412X/-</sup> Fluidigm scRNA-Seq data. **f**, Heatmap of ChIP-Seq read coverage at Gfi1-specific peaks where each row represents one peak that was called in the wild-type and each column represents a DNA-base position of the peak centered on each Gfi1 called peak in the indicated ChIP samples. The cluster color (left) indicates loci bound by Gfi1 alone (white) or by Gfi1 and Gfi1-R412X (black). **g-1**, Schematics of the indicated genomic loci displaying scATAC-Seq pseudobulk accessibility in the color-coded clusters (top) or ChIP-Seq reads and called peaks (bottom), with differentially accessible regions bound by Gfi1 shaded.



**Extended Data Figure 9. Fluidigm-based transcriptional analysis of *Gfi1*<sup>R412X/-</sup> genetic rescues.** **a**, FACS plots and **b**, representative cytopspins of adult murine bone marrow. **c-d** Graphical summary of colony-forming-unit (CFU) assays performed on c-Kit<sup>+</sup> bone marrow cells. G; granulocyte, M; monocyte, GM; granulocyte-monocyte, BFU-E; burst-forming-unit erythroid, GEMM; granulocyte, erythrocyte, monocyte, megakaryocyte. **e**, FACS plots of murine bone marrow cells isolated from *Irf8-eGFP* transgenic mice with the mean % Irf8-GFP<sup>high</sup> indicated. **f**, 3D FACS plots of bone marrow isolated from adult *Irf8-eGFP* mice. Events are pseudocolored for CD11b expression and arrows indicate changes in the

incidence of granulocytic populations. **g**, FACS plots and representative cytopspins of adult murine bone marrow populations sorted for scRNA-Seq. **h-i**, cellHarmony-assigned *Gfi1*<sup>R412X/R412X</sup> and *Gfi1*<sup>R412X/-</sup>*Irf8*<sup>+/-</sup> cells to wild-type reference Fluidigm scRNA-Seq populations (**h**,  $n = 86$  cells, **i**,  $n = 88$  cells). Each tick mark represents a single cell library. ICGS clusters are annotated (top). HSCP-1, haematopoietic stem cell progenitor; NK, natural killer T-cell progenitor; HSCP-2; Meg, megakaryocytic; Eryth, erythrocytic; DC, dendritic cell; MDP, monocyte dendritic cell progenitor; Multi-Lin\*, multi-lineage primed; cMoP, common monocyte progenitor; Mono, monocytic; MP, monocyte-committed progenitors; proNeu-1, neutrophil progenitor, proNeu-2; preNeu-1, neutrophil precursor, preNeu-2, preNeu-3; immNeu, immature neutrophil. FACS gates are annotated (right). **j**, Population distribution of Fluidigm scRNA-Seq data from **h**, **i**, Extended Data Fig. 4c, and Extended Data Fig. 6c. **j-k**, Fluidigm scRNA-Seq heatmaps (left) of genes that are genetically repaired in each cluster, with key genes indicated. Adjacent plot (right) of enriched biological processes in the indicated clusters. Scale bars in **b** and **g** represent 10  $\mu$ m. Cytopspin data in **b** are representative of three biological replicates. Data in **a**, **c**, and **d** are displayed as mean  $\pm$  s.e.m or mean in **e**. \*\*\*\*  $p < 0.0001$  as determined by two-tailed  $t$ -test in **a**, **c**, and **d**.



**Extended Data Figure 10. G-CSF pushed SCN-patient neutrophils are morphologically normal but functionally defective.**

Representative cytopspins of purified human peripheral blood neutrophils. The data is representative of one experiment per donor. Scale bars in represent 10  $\mu$ m.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank Harinder Singh for Gfi1 antisera, Herbert C. Morse for supplying *Irf8-GFP* mice, members of the Cincinnati Children's Hospital Medical Center (CCHMC) DNA Sequencing and Genotyping Core and the Research Flow Cytometry Core (supported in part by NIH AR-47363, NIH DK78392 and NIH DK90971) especially Alyssa Sproles for assistance with cytokine analyses. We thank Shawn Smith, Hung Chi Liang, and Kelly Rangel in the CCHMC Gene Expression Core for generating scRNA-Seq libraries. We thank Tess Newkold for excellent


technical assistance. We thank Harinder Singh, Jose Cancelas, Scott Kogan, Raphael Kopan, Jim Wells and Tanja Gruber for helpful questions and discussions. This work was partly funded by support from NIH DP1A1131080 (SS.W.) T32 ES007250 (to D.E.M.), S10RR027015 (to K.D.G.), and R01HL122661 (H.L.G.).

## References


1. Stoeckius M et al. Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods* 14, 865–868, doi:10.1038/nmeth.4380 (2017). [PubMed: 28759029]
2. Gilbert SF *Developmental Biology*, 6th edition. (Sinauer Associates, 2000).
3. An interactive online viewer of murine hematopoietic gene expression, <<http://www.altanalyze.org/ICGS/Neutrophil/Viewer.php>> (
4. DePasquale EAK et al. cellHarmony: cell-level matching and holistic comparison of single-cell transcriptomes. *Nucleic Acids Res*, doi:10.1093/nar/gkz789 (2019).
5. Stuart T et al. Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888–1902.e1821, doi:10.1016/j.cell.2019.05.031 (2019). [PubMed: 31178118]
6. Xia J et al. Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia. *Br J Haematol* 147, 535–542, doi:10.1111/j.1365-2141.2009.07888.x (2009). [PubMed: 19775295]
7. Person RE et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. *Nat Genet* 34, 308–312, doi:10.1038/ng1170 (2003). [PubMed: 12778173]
8. Wang H et al. A reporter mouse reveals lineage-specific and heterogeneous expression of IRF8 during lymphoid and myeloid cell differentiation. *J Immunol* 193, 1766–1777, doi:10.4049/jimmunol.1301939 (2014). [PubMed: 25024380]
9. Deshmukh HS et al. The microbiota regulates neutrophil homeostasis and host resistance to *Escherichia coli* K1 sepsis in neonatal mice. *Nat Med* 20, 524–530, doi:10.1038/nm.3542 (2014). [PubMed: 24747744]
10. Luedi PP et al. Computational and experimental identification of novel human imprinted genes. *Genome Res* 17, 1723–1730, doi:10.1101/gr.6584707 (2007). [PubMed: 18055845]
11. Bonthuis PJ et al. Noncanonical Genomic Imprinting Effects in Offspring. *Cell Rep* 12, 979–991, doi:10.1016/j.celrep.2015.07.017 (2015). [PubMed: 26235621]
12. Hock H et al. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. *Immunity* 18, 109–120 (2003). [PubMed: 12530980]
13. Belyaev NN et al. Induction of an IL7-R(+)-c-Kit(hi) myelolymphoid progenitor critically dependent on IFN-gamma signaling during acute malaria. *Nat Immunol* 11, 477–485, doi:10.1038/ni.1869 (2010). [PubMed: 20431620]
14. MacNamara KC et al. Infection-induced myelopoiesis during intracellular bacterial infection is critically dependent upon IFN-gamma signaling. *J Immunol* 186, 1032–1043, doi:10.4049/jimmunol.1001893 (2011). [PubMed: 21149601]
15. Mempel K, Pietsch T, Menzel T, Zeidler C & Welte K Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia. *Blood* 77, 1919–1922 (1991). [PubMed: 1708293]
16. Hock H et al. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. *Nature* 431, 1002–1007, doi:10.1038/nature02994 (2004). [PubMed: 15457180]
17. Karsunky H et al. Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. *Nat Genet* 30, 295–300, doi:10.1038/ng831 (2002). [PubMed: 11810106]
18. Zeng H, Yucel R, Kosan C, Klein-Hitpass L & Moroy T Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. *Embo j* 23, 4116–4125, doi:10.1038/sj.emboj.7600419 (2004). [PubMed: 15385956]
19. Abe T et al. Visualization of cell cycle in mouse embryos with Fucci2 reporter directed by Rosa26 promoter. *Development (Cambridge, England)* 140, 237–246, doi:10.1242/dev.084111 (2013).
20. Olsson A et al. Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. *Nature* 537, 698–702, doi:10.1038/nature19348 (2016). [PubMed: 27580035]

21. Yanez A et al. Granulocyte-Monocyte Progenitors and Monocyte-Dendritic Cell Progenitors Independently Produce Functionally Distinct Monocytes. *Immunity* 47, 890–902.e894, doi:10.1016/j.immuni.2017.10.021 (2017). [PubMed: 29166589]
22. Ng LG, Ostuni R & Hidalgo A Heterogeneity of neutrophils. *Nat Rev Immunol* 19, 255–265, doi:10.1038/s41577-019-0141-8 (2019). [PubMed: 30816340]
23. Farrell JA et al. Single-cell reconstruction of developmental trajectories during zebrafish embryogenesis. *Science*, doi:10.1126/science.aar3131 (2018).
24. Zhu YP et al. Identification of an Early Unipotent Neutrophil Progenitor with Pro-tumoral Activity in Mouse and Human Bone Marrow. *Cell Rep* 24, 2329–2341.e2328, doi:10.1016/j.celrep.2018.07.097 (2018). [PubMed: 30157427]
25. Drissen R et al. Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. *Nat Immunol* 17, 666–676, doi:10.1038/ni.3412 (2016). [PubMed: 27043410]
26. Kim MH et al. A late-lineage murine neutrophil precursor population exhibits dynamic changes during demand-adapted granulopoiesis. *Sci Rep* 7, 39804, doi:10.1038/srep39804 (2017). [PubMed: 28059162]
27. Evrard M et al. Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. *Immunity* 48, 364–379.e368, doi:10.1016/j.immuni.2018.02.002 (2018). [PubMed: 29466759]
28. Fang R et al. Fast and Accurate Clustering of Single Cell Epigenomes Reveals Cis-Regulatory Elements in Rare Cell Types. *bioRxiv*, 615179, doi:10.1101/615179 (2019).
29. Zweidler-Mckay PA, Grimes HL, Flubacher MM & Tschlis PN Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. *Mol Cell Biol* 16, 4024–4034, doi:10.1128/mcb.16.8.4024 (1996). [PubMed: 8754800]
30. Gillet LC et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. *Mol Cell Proteomics* 11, O111.016717, doi:10.1074/mcp.O111.016717 (2012).
31. Elsner J, Roesler J, Emmendorffer A, Lohmann-Matthes ML & Welte K Abnormal regulation in the signal transduction in neutrophils from patients with severe congenital neutropenia: relation of impaired mobilization of cytosolic free calcium to altered chemotaxis, superoxide anion generation and F-actin content. *Experimental hematology* 21, 38–46 (1993). [PubMed: 7678087]






**Figure 1. Neutropenia-patient-derived mutations induce steady-state murine dysgranulopoiesis and broad immune defects.**  
**a**, Schematic of *Gfi1* locus; locations of mutations introduced by genome editing. **b**, Immunoblot of adult murine Lineage<sup>Neg</sup> bone marrow. **c**, FACS plots with percentages of total adult peripheral blood, and cytopspins of FACS-sorted CD11b<sup>+</sup> Ly6g<sup>+</sup> cells. **d**, Colony-forming-unit (CFU) assays performed on Lineage<sup>Neg</sup> bone marrow cells. G; granulocyte, M; monocyte, GM; granulocyte-monocyte, BFU-E; burst-forming-unit erythroid, GEMM; granulocyte, erythrocyte, monocyte, megakaryocyte. **e**, FACS analysis of adult murine bone marrow. HSC, hematopoietic stem cell; LSK, Lineage<sup>Neg</sup> Sca-1<sup>+</sup> c-Kit<sup>+</sup>. **f**, Representative images of adult mice and spleens. **g-h**, Survival of mice infected with **g**, an LD<sub>50</sub> dose of *Candida albicans* or **h**, 5 × 10<sup>7</sup> CFU of *Staphylococcus aureus*. Mouse numbers in parentheses. **i**, FACS plots and **j**, cytopspins from R412X homozygotes. **k-l**, Survival of mice infected with **k**, an LD<sub>50</sub> dose of *C. albicans* or **l**, 5 × 10<sup>7</sup> CFU of *S. aureus*. Mouse numbers in parentheses. Data are displayed as mean ± s.e.m. from independent biological replicates in **c-e**, and **i**. Data in **b** represents 3 independent experiments. Images in **f** are representative of 2 littermate mice for each genotype. \* p < 0.05, \*\* p < 0.01, and \*\*\*\* p < 0.0001 as determined by two-tailed *t*-test in **c-e**, and **i** or by two-sided Mantel-Cox test in **g, h, k**, and **l**. The scale bars represent 10 μm in **c** and **j** and 1 cm in **f**.



**Figure 2. Cell states traversed during commitment to terminal granulopoiesis include a rare transitional state (bridging specification to commitment).**

**a**, FACS plot with annotated gates used to sort cells for scRNA-Seq (see Extended Data Fig. 4a; granulocyte-monocyte-progenitor and precursor “GMP-P” gate). **b**, 3D FACS plot of GMP-P gate (see Extended Data Fig. 4a). **c**, Quantified histological forms of FACS-sorted cells (from gates in **a**). **d**, Schematic of fluorescent cell cycle reporter and representative FACS plots of GMP-P gate from Fucci2 transgenic mice. **e**, 3D FACS plots of bone marrow isolated from adult mice bearing *Gfi1*, *Irf8* or *Myc* fluorescent-protein reporters, or *Vcam1* expression. Events are pseudocolored for CD11b expression. **f**, Bar chart displaying incidence and amplitude for selected genes (Fluidigm C1; see Extended Data Fig. 4c) ( $n = 509$  cells). ICGS clusters are annotated (top) FACS gates are annotated (bottom). **g**, Heatmap of correlation between gene expression and each displayed cluster (MarkerFinder). **h**, Bar chart displaying selected genes (same cells as in **f**). **i**, Heatmap of correlation between gene expression and each displayed cluster (MarkerFinder). **j-k**, Plots of ADT UMIs (10X 3’: see Extended Data Fig. 5b, e) where grey indicates all captured cells; **j**, red identifies cells within ICGS clusters (right). **k**, red or blue indicates the top 1% of cells expressing the indicated gene(s). **l**, URD pseudotime analysis (of data in Extended Data Fig. 5b), and transcriptional features, or normalized Z-scores of enriched biological processes (of data in Extended Data Fig. 4c). Data are representative of three independent biological replicates in **a**, **b**, **d**, and **e**. Data in **c** represents cumulative total cell numbers from one experiment using cells pooled from 3 male mice. Data in **g** and **i** display Pearson correlation values. LSK, Lineage<sup>Neg</sup> c-Kit<sup>+</sup> Sca-1<sup>+</sup>; CMP, common myeloid progenitor; LK CD34<sup>+</sup>, Lineage<sup>Neg</sup> c-Kit<sup>+</sup> Sca-1<sup>Neg</sup> CD34<sup>+</sup>.



**Figure 3. A single mutation in a lineage-determining transcription factor differentially impacts target gene expression in distinct cell states.**

**a**, cellHarmony differential expression heatmap. scRNA-Seq libraries from *Gfi1*<sup>R412X/-</sup> and *Gfi1*<sup>+/+</sup> mice were analyzed (10X 3' mod-GMP gate and Ly6g<sup>high</sup> GMP-P gate), then restricted to Gfi1 ChIP-Seq targets (841 out of 1462 total), and genes commonly deregulated across 10x and Fluidigm platforms are displayed (right)(see Extended Data Fig. 6k). Each row represents a single gene, each column the fold difference, and enriched Gene Ontology terms (left). **b**, Differential cicero gene activity scores correlated (top) or anticorrelated


(bottom) with scRNA-Seq differentially expressed genes (from panel **a**). **c**, Heatmaps of scATAC-Seq pseudo-bulk data from Gfi1 and Gfi1-R412X bound loci (black bars on left, and see Extended Data Fig. 8e). ICGS clusters (top). Each row is a gene locus (right). **d**, Schematic of the *Irf8* locus displaying scATAC-Seq pseudobulk accessibility with regions bound by Gfi1 shaded (top). ChIP-Seq reads (bottom). ICGS clusters (left). **e**, FACS plots and representative cytopins of FACS-sorted CD11b<sup>+</sup> Ly6g<sup>+</sup> cells from adult murine peripheral blood. In **e**, data are displayed as mean  $\pm$  s.e.m. from independent biological replicates; \*  $p < 0.05$  as determined by two-tailed *t*-test, and scale bars represent 10  $\mu$ m.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 4. Rescuing specification does not repair innate immune effector functions that are programmed after commitment.**

**a**, Heatmap of median-normalized values of antibody-dependent tags (ADT) from CITE-Seq of sorted wild-type mod-GMP-gate cells. **b**, Joint UMAP projection of CITE-Seq from the indicated genotypes, each dot represents one cell, and cluster identity is color coded (cellHarmony) to highlight genetic repair (*Gfi1<sup>R412X/R412X</sup>* and *Gfi1<sup>R412X/-</sup> Irf8<sup>+/-</sup>*) (also see Extended Data Fig. 7b). **c-d**, Heatmap of gene expression that is **c**, genetically repaired or **d**, not genetically repaired in each cluster (top), with representative genes indicated (right). **e-f**, Enriched Gene Ontology from **e**, genetically repaired genes (in **c**), or **f**, genes not genetically repaired (in **d**). **g**, Heatmap of genes that are differentially expressed in SCN-patient neutrophils (right), and their dynamic expression across murine wild-type clusters is shown (left). **h**, Enriched biological processes (from genes in **g**) (Grey dots; control versus female. Red dots: changes conserved to control versus male). **i**, Volcano plot displaying SWATH proteomics data. (Black dots: differential proteins between *Gfi1<sup>R412X/-</sup>* and *Gfi1<sup>+/-</sup>* neutrophils. Red dots: change conserved in *Gfi1<sup>R412X/-</sup>*, *Gfi1<sup>K403R/-</sup>* and *Gfi1<sup>R412X/R412X</sup>* neutrophils. **j-k**, Oxidative burst in purified neutrophils from **j**, murine bone marrow or **k**, human peripheral blood. Data in **j** and **k** are represented as mean ± s.e.m. from independent

biological replicates. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$  as determined by two-tailed  $t$ -test for **j** and **k**.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript